Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of bevacizumab + temsirolimus versus sunitinib versus bevacizumab + interferon alfa-2a as first-line treatment for metastatic renal cell carcinoma
2007-003369-42Phase 2Completed
- Sponsor
- Centre Léon Bérard
- Start
- Aug 2007
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in renal cell carcinoma (RCC) comparing Bevacizumab + temsirolimus, Sunitinib and Bevacizumab + interferon alfa-2a (3 arms). Primary endpoint: Non-progression rate at 48 weeks. Started Aug 2007; status: completed.
02
Drugs
bevacizumabtemsirolimussunitinibinterferon alfa
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2007-003369-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003369-42.